UNSPSC 51432302: Imidapril

This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BW7H1TJS22. European Medicines Agency schedules Imidapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08143MIG. Imidapril generally arises in the molecular formula C20H27N3O6.

UNSPSC 51432302 Imidapril, a Commodity code, covers specific pharmaceutical products that state and local governments procure for emergency medical services, health department programs, and multistate cooperative purchasing agreements. Recent solicitations show state and local agencies buying imidapril and related advanced life support medications, antiarrhythmic agents, and other generic pharmaceuticals through direct vendor relationships, cooperative purchasing vehicles, and emergency procurement channels. The work includes supplying finished pharmaceutical products with specified National Drug Codes, managing expiration and shelf-life compliance, arranging delivery and replacement logistics, and maintaining regulatory certifications including FDA approval, cGMP compliance, and Drug Supply Chain Security Act adherence. Issuing bodies range from individual city fire and emergency services departments to state health agencies and multistate cooperative purchasing organizations; recent activity shows participation from the City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple state and local facilities across participating jurisdictions.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications—including labetalol, epinephrine, adenosine, and diltiazem vials for Tampa Fire Rescue—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, carrying a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs, signaling longer-term procurement intent in pharmacy benefit management. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with contract awards effective July 1, 2026 and performance penalties ranging from $200 to $1,500 per violation. All opportunities require vendors to maintain comprehensive insurance, comply with safety and accessibility standards, and demonstrate pricing flexibility across multiple net-price and WAC-based models.